Cytokinetics Q2 Loss Wider Than Expected; MYQORZO Launch Gains Traction, ACACIA-HCM Positive, $760M Raise
CYTK has more than doubled off its 52-week low of $32.89.
Summary
Cytokinetics posted a wider-than-expected Q2 loss but delivered strong MYQORZO launch metrics, positive pivotal data for aficamten in nHCM, and a $760 million equity raise, positioning the company for global expansion.
Key Events · Earnings and Guidance · CYTK
-
Q2 Loss Misses Consensus
Net loss of $1.50 per share, wider than the consensus estimate of a narrower loss, driven by higher SG&A spending for the MYQORZO launch.
-
MYQORZO Launch Momentum
MYQORZO net product revenue reached $25.3 million in Q2, with over 700 prescribers and approximately 1,500 patients dispensed, over 80% on paid prescriptions.
-
ACACIA-HCM Phase 3 Positive
Aficamten met both primary endpoints in non-obstructive HCM, with statistically significant improvements in symptoms and exercise capacity; supplemental NDA submission planned for Q4 2026.
-
$760 Million Equity Raise
Completed a public offering of 11.34 million shares at $71.00 per share, generating net proceeds of $760.1 million; cash and investments now ~$1.7 billion.
Analysis · CYTK · Life Sciences
Cytokinetics reported a Q2 loss of $1.50 per share, missing consensus estimates, but the quarter was packed with strategic positives: MYQORZO generated $25.3 million in net product revenue in its early launch, the pivotal ACACIA-HCM trial in non-obstructive HCM met both primary endpoints, and the company raised $760 million in a public offering at $71 per share. The offering, while dilutive, was priced near the current $76 stock price, reflecting institutional demand. The company also raised its full-year expense guidance to support a potential 2027 nHCM launch. With $1.7 billion in cash, the balance sheet is fortified for the commercial build-out and pipeline advancement.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 984 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.83%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYTK was trading at $76.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $32.89 to $88.31. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.